Myleodysplastic syndromes (MDS) affects haematopoiesis within its sufferers, this leads to severe anaemia. Currently the way that the majority of patients are treated is to receive a blood transfusion. 

Asunercept, currently in development as a immuno-oncology for solid tumours and glioblastomas, was seen to interact with the same pathway which inhibits erythropoiesis within MDS patients. Following a phase II trial in glioblastoma the drug underwent a phase I trial in MDS showing a significant reduction in transfusion frequency. 

This trial was only carried out in 20 patients with a low-to-intermediate risk of MDS however these results are very positive. The drug was well tolerated up to 20mg/kg of body weight and will be looking to engage in further trials in the future.